Andreas Leiherer1, Axel Muendlein2, Christoph H Saely3, Janine Ebner4, Eva M Brandtner5, Peter Fraunberger6, Heinz Drexel7. 1. Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein; Medical Central Laboratories, Feldkirch, Austria. 2. Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein. 3. Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein. 4. Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Medical Central Laboratories, Feldkirch, Austria. 5. Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria. 6. Private University of the Principality of Liechtenstein, Triesen, Liechtenstein; Medical Central Laboratories, Feldkirch, Austria. 7. Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein; Drexel University College of Medicine, Philadelphia, PA, USA. Electronic address: vivit@lkhf.at.
Abstract
BACKGROUND: Uromodulin is a protein produced exclusively by the kidneys and present in urine and blood. In contrast to weak and in part contradictory study data on uromodulin in urine samples, the analysis of serum samples recently proved uromodulin's value as superior biomarker for ongoing kidney disease. Whether serum uromodulin is associated with cardiovascular event risk and whether it has predictive power for overall mortality is still unknown and has been evaluated in the present study. METHODS: We measured uromodulin in a series of 529 patients without acute coronary syndrome undergoing coronary angiography for the evaluation of established or suspected stable coronary artery disease (CAD) and prospectively recorded mortality as well as cardiovascular events in our patients during a follow-up of up to 8years. RESULTS: We recorded 95 deaths and 145 cardiovascular events over 8years. Serum uromodulin proved protective for overall mortality (HR=0.56 [95%CI 0.43-0.72]; p<0.001), even after full adjustment including eGFR, current smoking, diabetes, and CAD status (adj. HR=0.57 [95%CI 0.37-0.89]; p=0.014). Patients in the lowest tertile of serum uromodulin had a significantly higher cardiovascular event risk compared to patients in the medium and highest tertile (HR=of 1.45 (95%CI 1.04-2.02, p=0.027). The ratio between creatinine and uromodulin was significantly associated with kidney function (r=-0.322; p<0.001) and significantly predicted the incidence of cardiovascular events (HR of 1.26 [95%CI 1.12-1.41], p<0.001) and major cardiovascular events (HR of 1.37 [95%CI 1.21-1.56], p<0.001). CONCLUSION: We conclude that serum uromodulin is a valuable biomarker to predict overall mortality and cardiovascular events.
BACKGROUND:Uromodulin is a protein produced exclusively by the kidneys and present in urine and blood. In contrast to weak and in part contradictory study data on uromodulin in urine samples, the analysis of serum samples recently proved uromodulin's value as superior biomarker for ongoing kidney disease. Whether serum uromodulin is associated with cardiovascular event risk and whether it has predictive power for overall mortality is still unknown and has been evaluated in the present study. METHODS: We measured uromodulin in a series of 529 patients without acute coronary syndrome undergoing coronary angiography for the evaluation of established or suspected stable coronary artery disease (CAD) and prospectively recorded mortality as well as cardiovascular events in our patients during a follow-up of up to 8years. RESULTS: We recorded 95 deaths and 145 cardiovascular events over 8years. Serum uromodulin proved protective for overall mortality (HR=0.56 [95%CI 0.43-0.72]; p<0.001), even after full adjustment including eGFR, current smoking, diabetes, and CAD status (adj. HR=0.57 [95%CI 0.37-0.89]; p=0.014). Patients in the lowest tertile of serum uromodulin had a significantly higher cardiovascular event risk compared to patients in the medium and highest tertile (HR=of 1.45 (95%CI 1.04-2.02, p=0.027). The ratio between creatinine and uromodulin was significantly associated with kidney function (r=-0.322; p<0.001) and significantly predicted the incidence of cardiovascular events (HR of 1.26 [95%CI 1.12-1.41], p<0.001) and major cardiovascular events (HR of 1.37 [95%CI 1.21-1.56], p<0.001). CONCLUSION: We conclude that serum uromodulin is a valuable biomarker to predict overall mortality and cardiovascular events.
Authors: Dominik Steubl; Petra Buzkova; Pranav S Garimella; Joachim H Ix; Prasad Devarajan; Michael R Bennett; Paulo H M Chaves; Michael G Shlipak; Nisha Bansal; Mark J Sarnak Journal: Nephrol Dial Transplant Date: 2020-08-01 Impact factor: 5.992
Authors: Dominik Steubl; Markus P Schneider; Heike Meiselbach; Jennifer Nadal; Matthias C Schmid; Turgay Saritas; Vera Krane; Claudia Sommerer; Seema Baid-Agrawal; Jakob Voelkl; Fruzsina Kotsis; Anna Köttgen; Kai-Uwe Eckardt; Jürgen E Scherberich Journal: Clin J Am Soc Nephrol Date: 2020-04-14 Impact factor: 8.237
Authors: Petter Bjornstad; Pattara Wiromrat; Richard J Johnson; Rachel Sippl; David Z I Cherney; Randy Wong; Marian J Rewers; Janet K Snell-Bergeon Journal: Diabetes Care Date: 2018-11-27 Impact factor: 19.112
Authors: Radmila Micanovic; Kaice A LaFavers; Kavish R Patidar; Marwan S Ghabril; Emma H Doud; Amber L Mosley; Angela R Sabo; Shehnaz Khan; Tarek M El-Achkar Journal: Am J Physiol Renal Physiol Date: 2022-01-31
Authors: Cornelia Then; Christian Herder; Holger Then; Barbara Thorand; Cornelia Huth; Margit Heier; Christa Meisinger; Annette Peters; Wolfgang Koenig; Wolfgang Rathmann; Michael Roden; Michael Stumvoll; Haifa Maalmi; Thomas Meitinger; Andreas Lechner; Jürgen Scherberich; Jochen Seissler Journal: Clin Kidney J Date: 2020-09-06